JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2023. Vol. 68. № 1
DOI: 10.33266/1024-6177-2023-68-1-86-91
V.I. Chernov1,2, E.A. Dudnikova1, R.V. Zelchan1,2, O.D. Bragina1,2,
A.A. Medvedeva1, A.N. Rybina1, A.V. Muravleva1, T.L. Kravchuk1, V.E. Goldberg1
Single-Photon Emission Computed Tomography with 99mTс-1-Thio-D-glucose in Evaluation of the Effectiveness and Prediction of the Results of Treatment of Lymphoproliferative Diseases
1Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia
2 Research Centrum for Oncotheranostics, Tomsk Polytechnic University, Tomsk, Russia
Contact person: V.I. Chernov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Study of 99mTc-1-thio-D-glucose (99mTc-TG) SPECT using fore possibility to assess the effectiveness of therapy and predict the results of lymphomas treatment.
Material and methods: We analyzed 99mTc-TG SPECT data of 30 people with malignant lymphomas: before treatment (SPECT1), after two courses (SPECT2) and after completion of chemotherapy (SPECT3).
Results: By the results of SPECT2 analyzing, a complete metabolic response after two courses of chemotherapy (SPECT2–) was observed in 15 patients (50 %). In 15 patients, after 2 cycles of chemotherapy, a partial metabolic response (12 people) or no metabolic response
(3 people) was established. These patients constituted the SPECT2+ group.
After completion of chemotherapy, a complete metabolic response (SPECT3–) was diagnosed in 21 (70 %) patients. This effect was obtained in 15 (100 %) patients with SPECT2– and in 6 patients (40 %) with SPECT2+. Of the 15 patients in the SPECT2+ group, 9 (60 %) patients after completion of chemotherapy were diagnosed with a partial metabolic response (6 people) or metabolic progression (3 people).
By two-year follow-up of patients, show that remission was observed in 23 (77 %) patients (complete remission in 15 people, uncertain complete remission in 8 patients). The relapse group consisted of 7 (23 %) cases, while 4 patients had a relapse of the disease, and 3 had progression. In SPECT2+ group, relapse of the disease was observed in 6 (40 %) cases, and remission in 9 (60 %) patients. While in SPECT2– group 1 (7 %) person relapse was diagnosed and 14 (93 %) were in remission (p<0.05).
Conclusion: 99mTc-TG SPECT makes it possible to evaluate the results of lymphomas treatment with high efficiency. The presence of a complete metabolic response of the tumor after two courses of therapy indicates a high level of disease-free survival.
Keywords: 99mTc-1-thio-D-glucose, single photon emission computed tomography, Hodgkin’s lymphoma, Non-Hodgkin’s lymphomas, lymphoma therapy, prognosis
For citation: Chernov VI, Dudnikova EA, Zelchan RV, Bragina OD, Medvedeva AA, Rybina AN, Muravleva AV, Kravchuk TL, Goldberg VE. Single-Photon Emission Computed Tomography with 99mTс-1-Thio-D-glucose in Evaluation of the Effectiveness and Prediction of the Results of Treatment of Lymphoproliferative Diseases. Medical Radiology and Radiation Safety. 2023;68(1):86–91. (In Russian). DOI: 10.33266/1024-6177-2023-68-1-86-91
References
1. Poddubnaya I.V., Savchenko V.G. Rossiyskiye Klinicheskiye Rekomendatsii po Diagnostike i Lecheniyu Zlokachestvennykh Limfoproliferativnykh Zabolevaniy = Recommendations for the Diagnosis and Treatment of Malignant Lymphoproliferative Diseases. Мoscow Publ., 2018. 470 c. (In Russ.).
2. Barrington S.F., Mikhaeel N.G., Kostakoglu L., et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J. Clin. Oncol. 2014;32:3048–3058. DOI: 10.1200/JCO.2013.53.5229.
3. Dreyling M., Thieblemont C., Gallamini A. et al. ESMO Consensus Conferences: Guidelines on Malignant Lymphoma. Part 2: Marginal Zone Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma. Ann Oncol. 2013;24:857–877. DOI: 10.1093/annonc/mds643.
4. Radford J., Illidge T., Counsell N. et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. New England Journal of Medicine. 2015;372;17:1598–1607. DOI: 10.1056/NEJMoa1408648.
5. Chanchikova N.G., Chernov V.I., Dudnikova Ye.A., et al. The Role of 18F-FDG PET/CT in Evaluation of Therapy Effectiveness and Prognosis of Lymphomas. Byulleten Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2021;20;2:120–129. DOI: org/10.20538/1682-0363-2021-2-120-129 (In Russ.).
6. Chernov V.I., Dudnikova Ye.A., Goldberg V.Ye., et al. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2018;63;6:41–50. DOI: 10.12737/article_5c0b8d72a8bb98.40545646 (In Russ.).
7. Chanchikova N.G., Dudnikova Ye.A., Karlova Ye.A., et al. Possibilities of 18F-FDG PET/CT in the diagnosis and staging of lymphomas. Voprosy Onkologii = Problems in Oncology. 2019;65;1:147–153. DOI: org/10.37469/0507-3758-2019-65-1-147-153 (In Russ.).
8. Chernov V.I., Dudnikova Ye.A., Goldberg V.Ye., et al. Single-Photon Emission Computerized Tomography in the Diagnosis and Monitoring of Lymphomas. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2019;64;3:58–63. DOI: 10.12737/article_5cf3dfefe60b13.90120976 (In Russ.).
9. Zeltchan R., Medvedeva A., Sinilkin I., et al. Experimental Study of Radiopharmaceuticals Based on Technetium-99m Labeled Derivative of Glucose for Tumor Diagnosis. IOP Conference Series. Materials Science and Engineering. 2016. DOI: 10.1088/1757-899X/135/1/012054.
10. Zelchan R.V., Medvedeva A.A., Sinilkin I.G., et al. Study of Functional Suitability Tumor Tropism Radiopharmaceuticals 99mTc-1-Thio-D-Glucose in the Experiment. Molekulyarnaya Meditsina = Molecular Medicine. 2018;16;2:54–57. DOI: https://doi.org/10.29296/24999490-2018-03-11 (In Russ.).
11. Chernov V.I., Medvedeva A.A., Sinilkin I.G., et al. Development Radiopharmaceuticals for Nuclear Medicine in Oncology. Meditsinskaya Vizualizatsiya = Medical Visualization. 2016;2:63–66 (In Russ.).
12. Chernov V.I., Dudnikova Ye.A., Zelchan R.V., et al. The First Experience of Using 99mTc-1-Thio-d-Glucose for Single-Photon Emission Computed Tomography Imaging of Lymphomas. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2018;17;4:81–87. DOI: 10.21294/1814-4861-2018-17-4-81-87 (In Russ.).
13. Dudnikova Ye.A., Chernov V.I., Muravleva A.V., et al. Metabolic Single-Photon Emission Computed Tomography with the New Radiopharmaceutical 99mTc-1-Thio-D-Glucose in the Diagnosis and Monitoring of the Primary Breast Lymphoma (Case Report). Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2020;19;5:145–153. doi: 10.21294/1814-4861-2020-19-5-145-153 (In Russ.).
14. Muravleva A.V., Chernov V.I., Dudnikova Ye.A., et al. Metabolic single-Photon Emission Computed Tomography with «99mTc-1-Thio-D-Glucose» - New Possibilities for Hodgkin’s Lymphoma Staging. Rossiyskiy Elektronnyy Zhurnal Luchevoy Diagnostiki = Russian Electronic Journal of Radiology. 2021;11;3:171–177. DOI: 10.21569/2222-7415-2021-11-3-171-177 (In Russ.).
15. Chernov V., Dudnikova E., Zelchan R., et al. Phase I Clinical Trial Using [99mTc]Tc-1-Thio-D-Glucose for Diagnosis of Lymphoma Patients. Pharmaceutics. 2022;14:1274. https://doi.org/10.3390/pharmaceutics14061274.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.09.2022. Accepted for publication: 25.11.2022.